智通财经网·2026-02-26 08:53Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue reaching 1.068 billion RMB, marking a year-on-year growth of 26.18% and a return to profitability with a net profit of 27.87 million RMB [1][2] Financial Performance - Total revenue for the reporting period was 1.068 billion RMB, reflecting a year-on-year increase of 26.18% [1][2] - The net profit attributable to the parent company was 27.87 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB, with the weighted average return on equity turning positive [2] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to significant savings in various expenses [2] - Resource allocation was optimized, contributing to improved operational efficiency during the reporting period [2] Product Development and Support - The company continued to focus on innovation and commercialization, with the growth of its first quadrivalent meningococcal vaccine, Manhaixin® [1] - The company received government grants and international research funding, which contributed to non-recurring income during the reporting period [1]